<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05000450</url>
  </required_header>
  <id_info>
    <org_study_id>ALLO-605-201</org_study_id>
    <secondary_id>IGNITE Study</secondary_id>
    <nct_id>NCT05000450</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma</brief_title>
  <official_title>A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-647 and ALLO-605, an Anti- BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allogene Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allogene Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the ALLO-605-201 study is to assess the safety, efficacy, and cell kinetics of&#xD;
      ALLO605 in adults with relapsed or refractory multiple myeloma after a lymphodepletion&#xD;
      regimen comprising fludarabine, cyclophosphamide, and ALLO-647.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 6, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Proportion of subjects experiencing Dose Limiting Toxicities at increasing doses of ALLO-605 that will determine MTD/MAD and select the recommended Phase 2 dose (RP2D) of ALLO-605.</measure>
    <time_frame>28 days</time_frame>
    <description>Dose limiting toxicity is defined as protocol-defined ALLO-605 related adverse events with onset within 28 days following infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: Proportion of patients experiencing Dose Limiting Toxicities with ALLO-647 [administered in combination with fludarabine/cyclophosphamide administered prior to ALLO-605]</measure>
    <time_frame>30 days</time_frame>
    <description>Dose-limiting toxicity is defined as protocol-defined ALLO-647-related adverse events with onset within 30 days following 1st infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: To assess clinical efficacy of ALLO-605 as measured by overall response rate (ORR)</measure>
    <time_frame>12 months of study follow-up</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Relapsed/Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>ALLO-605, ALLO-647</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>ALLO-605</intervention_name>
    <description>ALLO-605 is an anti-BCMA, TRAC/CD52 allogeneic edited, intracellular cytokine signaling containing, CAR T cell product</description>
    <arm_group_label>ALLO-605, ALLO-647</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALLO-647</intervention_name>
    <description>ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen</description>
    <arm_group_label>ALLO-605, ALLO-647</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Chemotherapy for lymphodepletion</description>
    <arm_group_label>ALLO-605, ALLO-647</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Chemotherapy for lymphodepletion</description>
    <arm_group_label>ALLO-605, ALLO-647</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented diagnosis of relapsed/refractory multiple myeloma (MM)&#xD;
&#xD;
          -  Subjects must have measurable disease&#xD;
&#xD;
          -  Subjects must have received â‰¥3 prior MM lines of therapy&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Adequate hematologic, renal, liver, pulmonary, and cardiac functions&#xD;
&#xD;
          -  Life expectancy of at least 3 months without treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with known active or history of central nervous system (CNS) or&#xD;
             leptomeningeal involvement of myeloma or plasma cell leukemia&#xD;
&#xD;
          -  Current or history of thyroid disorder (including hyperthyroidism), except for&#xD;
             subjects with hypothyroidism controlled on a stable dose of hormone replacement&#xD;
             therapy&#xD;
&#xD;
          -  Autologous stem cell transplantation within last 6 weeks prior to the start of&#xD;
             lymphodepletion&#xD;
&#xD;
          -  Any prior allogeneic hematopoietic stem cell transplantation&#xD;
&#xD;
          -  Systemic anti-cancer therapy within 2 weeks prior to the start of lymphodepletion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sarah Cannon/Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. David's South Austin Medical Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 4, 2021</study_first_submitted>
  <study_first_submitted_qc>August 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAR T</keyword>
  <keyword>Cell Therapy</keyword>
  <keyword>Allogeneic Cell Therapy</keyword>
  <keyword>Cellular Immuno-therapy</keyword>
  <keyword>AlloCAR T</keyword>
  <keyword>ALLO-605</keyword>
  <keyword>ALLO-647</keyword>
  <keyword>Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

